Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 6/20 | 0.60 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.48 |
| ▸ | AKT1 | P31749 | 3/20 | 0.45 |
| ▸ | MYLK4 | Q86YV6 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3024565 | 0.87 | AKT2 (0.56) | AKT2ROCK1ROCK2AKT1MYLK4 | |
| SCHEMBL3025775 | 0.86 | AKT2 (0.55) | AKT2ROCK1ROCK2AKT1MYLK4 | |
| SCHEMBL3030114 | 0.85 | AKT2 (0.63) | AKT2ROCK1ROCK2AKT1MYLK4 | |
| SCHEMBL3025930 | 0.84 | AKT2 (0.59) | AKT2ROCK1ROCK2AKT1MYLK4 | |
| SCHEMBL3024709 | 0.84 | AKT2 (0.61) | AKT2ROCK1ROCK2AKT1MYLK4 | |
| SCHEMBL3013100 | 0.83 | ROCK2 (0.54) | AKT2ROCK1ROCK2AKT1 | |
| SCHEMBL1979239 | 0.82 | AKT2 (0.58) | AKT2ROCK1ROCK2AKT1 | |
| SCHEMBL3025710 | 0.81 | AKT2 (0.57) | AKT2ROCK1ROCK2AKT1MYLK4 | |
| SCHEMBL1977536 | 0.80 | AKT2 (0.54) | AKT2ROCK1ROCK2AKT1 | |
| SCHEMBL6001484 | 0.80 | HRH1 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ERBB2, ABL1, GRK2 | AKT2 88/4885ROCK1 590/4885ROCK2 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.